ArticleNPJ systems biology and applications2022
Comprehensive network medicine-based drug repositioning via integration of therapeutic efficacy and side effects.
Article in NPJ systems biology and applications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Artificial intelligence in clinical trials-state of the evidence, gaps, and next steps.EClinicalMedicine · 2026Review
- Network-based analysis and multi-omics approaches for biology and medicine.Biotechnology reports (Amsterdam, Netherlands) · 2026Article
- Targeting protein protein interactions and their modulators to enable new therapeutic strategies for human diseases.NPJ systems biology and applications · 2026Review
- Artificial Intelligence to Guide Repurposing of Drugs.Annual review of medicine · 2026Review
- Identification of osteoarthritis-related genes and potential drugs based on single cell RNA-seq data.Molecular medicine (Cambridge, Mass.) · 2025Article
- Data-driven strategies for drug repurposing: insights, recommendations, and case studies.Briefings in bioinformatics · 2025Article
- Prioritizing repurposable drugs for Alzheimer's disease using network-based analysis with concurrent assessment of Long QT syndrome risk.Biotechnology reports (Amsterdam, Netherlands) · 2025Article
- Phenotypic similarity of adverse drug reactions and disease phenotypes is a bridge to mechanistic discovery.npj drug discovery · 2025Article
- The coming era of proteomics-driven precision medicine.National science review · 2025Review
- Computational Drug Repositioning in Cardiorenal Disease: Opportunities, Challenges, and Approaches.Proteomics · 2025Article
- Exploring common mechanisms of adverse drug reactions and disease phenotypes through network-based analysis.Cell reports methods · 2025Article
- Article
- Drug repositioning pipeline integrating community analysis in drug-drug similarity networks and automated ATC community labeling to foster molecular docking analysis.Frontiers in bioinformatics · 2025Article
- Precision cardiovascular medicine: shifting the innovation paradigm.Frontiers in science · 2025Article
- DREAMER: Exploring Common Mechanisms of Adverse Drug Reactions and Disease Phenotypes through Network-Based Analysis.bioRxiv : the preprint server for biology · 2024Article
- Decoding the Foodome: Molecular Networks Connecting Diet and Health.Annual review of nutrition · 2024Review
- HMMF: a hybrid multi-modal fusion framework for predicting drug side effect frequencies.BMC bioinformatics · 2024Article
- Network medicine: an approach to complex kidney disease phenotypes.Nature reviews. Nephrology · 2023Review
- Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations.Circulation research · 2023Review
- Transcriptomics-based network medicine approach identifies metformin as a repurposable drug for atrial fibrillation.Cell reports. Medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Despite advances in modern medicine that led to improvements in cardiovascular outcomes, cardiovascular disease (CVD) remains the leading cause of mortality and morbidity globally. Thus, there is an urgent need for new approaches to improve CVD drug treatments. As the development time and cost of drug discovery to clinical application are excessive, alternate strategies for drug development are warranted. Among these are included computational approaches based on omics data for drug repositioning, which have attracted increasing attention. In this work, we developed an adjusted similarity measure implemented by the algorithm SAveRUNNER to reposition drugs for cardiovascular diseases while, at the same time, considering the side effects of drug candidates. We analyzed nine cardiovascular disorders and two side effects. We formulated both disease disorders and side effects as network modules in the human interactome, and considered those drug candidates that are proximal to disease modules but far from side-effects modules as ideal. Our method provides a list of drug candidates for cardiovascular diseases that are unlikely to produce common, adverse side-effects. This approach incorporating side effects is applicable to other diseases, as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.